Sanofi is acquiring Dynavax Technologies Corporation for $15.50 per share, enhancing its adult immunization portfolio with a marketed hepatitis B vaccine and a shingles vaccine candidate.

Target Company Overview

Sanofi has announced its intention to acquire Dynavax Technologies Corporation (Dynavax), a publicly traded vaccine company renowned for its innovative products. This acquisition strategically enhances Sanofi’s portfolio, particularly in adult immunization, by incorporating Dynavax’s marketed adult hepatitis B vaccine, HEPLISAV-B®, as well as a promising shingles vaccine candidate currently in phase 1/2 clinical trials. HEPLISAV-B is distinguished by its two-dose regimen administered over a month, which achieves higher seroprotection levels more rapidly compared to traditional three-dose vaccines that take six months to complete.

Dynavax also possesses a robust pipeline of vaccine projects aimed at addressing critical health needs. By blending its offerings with Sanofi’s global development and commercial capabilities, Dynavax aims to increase its market impact significantly. Both companies are aligned in their commitment to enhancing public health through advanced vaccination strategies.

Industry Overview in the U.S.

The adult vaccination sector in the United States represents a critical and often underserved market. Currently, an estimated 100 million adults born before 1991 remain unvaccinated, placing them at a heightened risk f